Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types. OBJECTIVE: To investigate treatment outcomes of dupilumab, methotrexate, and ciclosporin, and morphological phenotypes in atopic dermatitis patients, stratified by Fitzpatrick skin type. METHODS: In an observational prospective cohort study, pooling data from the Dutch TREAT (TREatment of ATopic eczema) NL ( and UK-Irish A-STAR (Atopic eczema Systemic TherApy Register; registries, data on morphological phenotypes and treatment outcomes were investigated. RESULTS: A total of 235 patients were included (light skin types [LST]: Fitzpatrick skin type 1-3, n = 156 [Ethnicity, White: 94.2%]; dark skin types [DST]: skin type 4-6, n = 68 [Black African/Afro-Caribbean: 25%, South-Asian: 26.5%, and Hispanics: 0%]). DST were younger (19.5 vs 29.0 years; P  .05). LIMITATIONS: Unblinded, non-randomized. CONCLUSION: Atopic dermatitis differs in several characteristics between LST and DST. Skin type may influence treatment effectiveness of dupilumab.

Original publication




Journal article



Publication Date





14 - 24


AD, atopic dermatitis, AE, adverse event, DLQI, Dermatology Life Quality Index, DST, Dark Skin Type(s), EASI, Eczema Area and Severity Index, IQR, interquartile range, LST, Light Skin Type(s), NRS, Numerical Rating Scale, POEM, Patient-Oriented Eczema Measure, SD, Standard Deviation, atopic dermatitis, atopic eczema, ciclosporin, daily practice, dupilumab, effectiveness, ethnicity, methotrexate, morphology, race, registry, routine clinical care, safety, skin type, systemic treatment